NEU²

new drugs
against
neurological diseases

 
 

Partners: Merck KGaA

Merck KGaA

Frankfurter Straße 250
64293 Darmstadt

Merck is a global pharmaceutical and chemical enterprise with around 33,000 employees in 60 countries.

Merck Serono is the division for innovative prescription pharmaceuticals of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs. In the United States and Canada, EMD Serono operates through separately incorporated affiliates.

Merck Serono has leading brands serving patients with cancer (Erbitux®, cetuximab), multiple sclerosis (Rebif®, interferon beta-1a), infertility (Gonal-f®, follitropin alfa), endocrine and metabolic disorders (Saizen® and Serostim®, somatropin), (Kuvan®, sapropterin dihydrochloride) as well as cardiometabolic diseases (Glucophage®, metformin), (Concor®, bisoprolol), (Euthyrox®, levothyroxine). Not all products are available in all markets.

With an annual R&D expenditure of around € 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in autoimmune and inflammatory diseases.

Ansprechpartner / Contact person:

Dr. Tomas Roztocil
Merck Serono Communications
Tel.: +41 22 4143864
Fax: +41 22 4143003
Email: tomas.roztocil@merckserono.net
URL: www.merck.de